<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03084250</url>
  </required_header>
  <id_info>
    <org_study_id>High risk of HCC</org_study_id>
    <nct_id>NCT03084250</nct_id>
  </id_info>
  <brief_title>The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC</brief_title>
  <official_title>A Prospective, Randomized, Open-label Study of the Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Nanhui Nanhua Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Nanhui Nanhua Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CHB subjects who are cirrhosis, will be randomized to two groups.&#xD;
&#xD;
      The subjects who go into group A will be treated by nucleotide analogue (NA) combination with&#xD;
      peginterferon alfa-2a,180μg/week for 48 weeks.&#xD;
&#xD;
      The subjects who go into group B will be treated by nucleotide analogue (NA) only for 48&#xD;
      weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized, open-label study.&#xD;
&#xD;
      The CHB subjects who are cirrhosis will be randomized to two groups.&#xD;
&#xD;
      The subjects who go into group A will be treated by nucleotide analogue (NA) combination with&#xD;
      peginterferon alfa-2a,180μg/week for 48 weeks.&#xD;
&#xD;
      The subjects who go into group B will be treated by nucleotide analogue (NA) only for 48&#xD;
      weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 10, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects who develop to hepatocellular carcinoma during 5 years</measure>
    <time_frame>5 years</time_frame>
    <description>The number of subjects develop to hepatocellular carcinoma during 5 years will be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who achieve HBeAg loss and HBeAg seroconversion</measure>
    <time_frame>year 1,2,3,4,5</time_frame>
    <description>The number of subjects with HBeAg loss and HBeAg seroconversion at year 1 ,2,3,4 and 5 will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who achieve HBsAg loss and HBsAg seroconversion</measure>
    <time_frame>year 1,2,3,4,5</time_frame>
    <description>The number of subjects with HBsAg loss and HBsAg seroconversion at year 1, 2,3,4 and 5 will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The factor such as HBsAg level related to the incidence of HCC development</measure>
    <time_frame>year 1</time_frame>
    <description>The HBsAg level at year 1 will be measured, to assess whether the quantitative HBsAg level related to the incidence of HCC development</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nucleotide analogue</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subjects will be treated by nucleotide analogue (NA) only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon Alfa-2A</intervention_name>
    <description>180μg/week, 48 weeks; 135μg/week,48weeks</description>
    <arm_group_label>Combination</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir, entecavir,tenofovir, either of them</intervention_name>
    <description>Adefovir, entecavir,tenofovir, either of them is ok</description>
    <arm_group_label>nucleotide analogue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients with age ≥18 and ≤65 years;&#xD;
&#xD;
          2. There should be evidences that HBsAg has been positive for more than 6 months with&#xD;
             HBsAb and HBeAb negative; HBV-related cirrhosis&#xD;
&#xD;
          3. Women without ongoing pregnancy or breast feeding and both women and men willing to&#xD;
             take an effective contraceptive measure during the treatment;&#xD;
&#xD;
          4. Agree to participate in the study and sign the patient informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treated by immunosuppressant,immunomodulator,Systemic cytotoxic drug,herbs or HBIg&#xD;
             within 6 months prior to the first dose of treatment;&#xD;
&#xD;
          2. ALT≥10 X ULN or total bilirubin ≥2 X ULN;&#xD;
&#xD;
          3. Allergic history to interferon;&#xD;
&#xD;
          4. Co-infection with active hepatitis A, hepatitis C, hepatitis D and/or human&#xD;
             immunodeficiency virus (HIV);&#xD;
&#xD;
          5. Child-Pugh scores &gt;7;&#xD;
&#xD;
          6. History or other evidence of a medical condition associated with chronic liver disease&#xD;
             other than viral hepatitis (e.g., hemochromatosis, autoimmune hepatitis, metabolic&#xD;
             liver disease, alcoholic liver disease, toxin exposures, thalassemia);&#xD;
&#xD;
          7. Pregnant or breast-feeding Women;&#xD;
&#xD;
          8. Consuming alcohol in excess of 20g/day for women and 30g/day for men within 6 months&#xD;
             prior to enrollment or drug taking history;&#xD;
&#xD;
          9. ANC(absolute neutrophil count)&lt;1.5x 10^9/L or PLT(platelet count)&lt;90x 10^9/L&#xD;
&#xD;
         10. Creatinine over upper limit of normal;&#xD;
&#xD;
         11. History of severe psychiatric disease, especially depression. Severe psychiatric&#xD;
             disease is defined as major depression or psychosis that treated with antidepressant&#xD;
             medication or a major tranquilizer at therapeutic doses respectively at any time prior&#xD;
             to 3 months or any history of the following: a suicidal attempt hospitalization for&#xD;
             psychiatric disease, or a period of disability due to a psychiatric disease;&#xD;
&#xD;
         12. History of immunologically mediated disease, (e.g., inflammatory bowel disease,&#xD;
             idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia,&#xD;
             scleroderma, rheumatoid arthritis etc.);&#xD;
&#xD;
         13. History of esophageal varices bleeding or other evidence of esophageal varices&#xD;
             bleeding or other symptoms consistent with decompensated liver disease;&#xD;
&#xD;
         14. History of severe cardiac disease (e.g., New York Heart Association Functional Class&#xD;
             III or IV, myocardial infarction within 6 months, ventricular tachyarrhythmias&#xD;
             requiring ongoing treatment, unstable angina or other significant cardiovascular&#xD;
             diseases);&#xD;
&#xD;
         15. Hemodialysis patients or patients with renal insufficiency;&#xD;
&#xD;
         16. History of a severe seizure disorder or current anticonvulsant use;&#xD;
&#xD;
         17. Major organ transplantation or other evidence of severe illness, malignancy, or any&#xD;
             other conditions, which would make the patient, in the opinion of the investigator,&#xD;
             unsuitable for the study;&#xD;
&#xD;
         18. History of thyroid disease poorly controlled on prescribed medications;&#xD;
&#xD;
         19. Evidence of severe retinopathy or clinically relevant ophthalmologic disorder;&#xD;
&#xD;
         20. History of other severe disease or evidence of other severe disease or any other&#xD;
             illness or conditions that the investigator believe that patients are not suitable to&#xD;
             join in the study;&#xD;
&#xD;
         21. Patients included in another trial or having been given investigational drugs within&#xD;
             12 weeks prior to screening;&#xD;
&#xD;
         22. AFP(alpha feto protein)&gt;50ng/ml and/or evidence of hepatocellular carcinoma;&#xD;
&#xD;
         23. Patients treated with Telbivudine;&#xD;
&#xD;
         24. Other disease should exclusive considered by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chenbo Hu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanhua Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nanhua Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>March 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2017</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Nanhui Nanhua Hospital</investigator_affiliation>
    <investigator_full_name>Chenbo Hu</investigator_full_name>
    <investigator_title>Dr.Chenbo Hu</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Adefovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

